BMRN
Q4 2026 EPS Estimate
$1.38
Oct 26, 2026 · Reports after close
Revenue Estimate
$1.03B
FY2026E EPS$5.03
FY2027E EPS$6.62

Analyst Sentiment

Wall St. Consensus
Buy
29 analysts·High coverage
70
Score
23 Buy (79%)6 Hold (21%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2379%
Hold
621%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$59.00
-10.8%
Consensus
$97.50
+47.5%
Bull
$124.00
+87.5%
12-Month Target Range29 analysts
$59.00$97.50$124.00
Current $66.12Consensus
Current Price
$66.12
Upside to Consensus
$31.38

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+14.05%
EPS+31.56%
FY2028
Rev+7.92%
EPS+17.18%
FY2029
Rev+8.19%
EPS+13.99%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$3.91B$4.45B$4.81B$5.20B$5.50B
Low$3.89B$4.26B$4.43B$5.01B$5.30B
High$3.94B$4.76B$5.22B$5.43B$5.75B
EBITDA Avg$535M$610M$659M$712M$753M
Low$532M$584M$607M$686M$726M
High$539M$652M$715M$744M$787M
EBIT Avg$372M$424M$458M$495M$524M
Low$370M$406M$422M$477M$504M
High$375M$453M$497M$517M$547M
Net Income Avg$993M$1.29B$1.49B$1.74B$1.89B
Low$971M$997M$568M$1.66B$1.80B
High$1.01B$1.52B$2.22B$1.85B$2.00B
EPS Avg$5.03$6.62$7.75$8.84$9.57
Low$4.92$5.05$2.88$8.41$9.11
High$5.10$7.69$11.23$9.35$10.13
Analysts (Rev / EPS)19 / 1619 / 1619 / 159 / 915 / 6
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$1.03B$1.13B$1.06B$1.09B$1.12B$1.14B
Low$988M$1.10B$1.03B$1.06B$1.08B$1.11B
High$1.06B$1.15B$1.10B$1.13B$1.16B$1.18B
EBITDA Avg$141M$154M$145M$150M$153M$157M
Low$135M$150M$141M$145M$148M$152M
High$145M$157M$150M$155M$158M$162M
EBIT Avg$98M$107M$101M$104M$107M$109M
Low$94M$104M$98M$101M$103M$105M
High$101M$109M$104M$108M$110M$113M
Net Income Avg$263M$340M$290M$310M$331M$366M
Low$223M$305M$278M$297M$317M$351M
High$287M$367M$303M$324M$345M$382M
EPS Avg$1.35$1.75$1.49$1.60$1.70$1.89
Low$1.15$1.57$1.43$1.53$1.63$1.81
High$1.48$1.89$1.56$1.67$1.78$1.97
Analysts (Rev / EPS)14 / 1114 / 119 / 47 / 47 / 713 / 4

Earnings Surprises

Recent Analyst Actions

Aug 18, 2026BMO Capital
BioMarin initiated with an Outperform at BMO Capital
Target:$98.00
+46.3%from $66.99
Aug 18, 2026H.C. Wainwright
BioMarin price target lowered to $59 from $60 at H.C. Wainwright
Target:$59.00
-13.0%from $67.79
Aug 17, 2026Piper Sandler
BioMarin price target raised to $88 from $82 at Piper Sandler
Target:$88.00
+30.6%from $67.36
Aug 17, 2026Barclays
BioMarin price target raised to $111 from $105 at Barclays
Target:$111.00
+64.8%from $67.36
Aug 10, 2026Canaccord Genuity
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
Target:$114.00
+78.7%from $63.81
Aug 7, 2026Raymond James
BioMarin price target raised to $105 from $100 at Raymond James
Target:$105.00
+64.6%from $63.80
Aug 7, 2026Morgan Stanley
BioMarin price target raised to $124 from $119 at Morgan Stanley
Target:$124.00
+94.2%from $63.84
Aug 7, 2026Stifel Nicolaus
BioMarin price target raised to $70 from $68 at Stifel
Target:$70.00
+10.1%from $63.55
Aug 7, 2026Oppenheimer
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $97 at Oppenheimer
Target:$97.00
+57.8%from $61.46
Jul 7, 2026RBC Capital
BioMarin price target lowered to $62 from $66 at RBC Capital
Target:$62.00
+5.5%from $58.79
May 22, 2026Canaccord Genuity
BioMarin price target lowered to $111 from $116 at Canaccord
Target:$111.00
+105.2%from $54.10
May 18, 2026Leerink Partners
BioMarin price target lowered to $62 from $64 at Leerink
Target:$62.00
+24.8%from $49.67
May 18, 2026H.C. Wainwright
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
Target:$50.00
-0.3%from $50.15
May 11, 2026Goldman Sachs
BioMarin reinstated with a Neutral at Goldman Sachs
Target:$69.00
+27.6%from $54.06
May 5, 2026Evercore ISI
BioMarin price target raised to $120 from $110 at Evercore ISI
Target:$120.00
+120.8%from $54.36
May 5, 2026Tudor Pickering
BioMarin price target lowered to $82 from $94 at Bernstein
Target:$82.00
+47.9%from $55.46
Apr 27, 2026Morgan Stanley
BioMarin resumed with an Overweight at Morgan Stanley
Target:$120.00
+125.6%from $53.18
Mar 12, 2026Jefferies
Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign"
Target:$103.00
+72.1%from $59.86
Mar 3, 2026Barclays
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
Target:$105.00
+75.8%from $59.74
Mar 2, 2026Loop Capital Markets
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
Target:$105.00
+73.6%from $60.47
Feb 26, 2026Canaccord Genuity
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord
Target:$104.00
+72.6%from $60.26
Feb 24, 2026Oppenheimer
BioMarin price target lowered to $95 from $98 at Oppenheimer
Target:$95.00
+51.0%from $62.92
Feb 24, 2026Stifel Nicolaus
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel
Target:$68.00
+10.7%from $61.44
Feb 18, 2026Wells Fargo
BioMarin price target raised to $75 from $70 at Wells Fargo
Target:$75.00
+25.1%from $59.95
Feb 6, 2026Piper Sandler
BioMarin price target lowered to $84 from $122 at Piper Sandler
Target:$84.00
+47.0%from $57.15
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.